Antitumoral Activity of Multiferon® (HulFN-alpha-Le) in Experimental Murine Melanoma Model
Bruno Blaya*, Idoia Ortega-Martínez, Erika Alonso Tejerina, Teresa G Granda and Maria D Boyano
Department of Cell Biology and Histology, Faculty of Medicine and Dentistry, University of the Basque Country, Leioa, Bizkaia, Spain
- *Corresponding Author:
- Bruno Blaya
Department of Dermatology
Cruces University Hospital/BioCruces Heath Research Institute
Plaza de Cruces s/n, 48903 Barakaldo
Tel: +34 94600 6073
E-mail: [email protected]
Received date: August 11, 2012; Accepted date: September 07, 2012; Published date: September 23, 2012
Citation: Blaya B, Ortega-Martínez I, Tejerina EA, Granda TG, Boyano MD (2012) Antitumoral Activity of Multiferon® (HulFN-alpha-Le) in Experimental Murine Melanoma Model. J Clin Exp Dermatol Res 3:159.. doi:10.4172/2155-9554.1000159
Copyright: ©2012 Blaya B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Multiferon® (HuIFN-alpha-Le) (MF) is a natural interferon alpha used in several countries for the treatment of selected viral infections and as an adjuvant treatment in different types of cancer, including melanoma.
We have examined the influence of MF in vitro and in vivo in murine melanoma cells. B16F10 cells were treated with MF at different concentrations ranging from 0 to 1000 IU/mL and this substance had no effect on cell proliferation, migration or clonogenic abilities of the tumoral cells. However, in vivo studies with murine models after subcutaneous implantation of B16F10 cells showed that tumor volumes measured during the experiment and at sacrifice were significantly smaller in mice receiving MF (90 IU/mice 3 times a week) than in the control group (p<0.005). MF was well tolerated and no body weight loss or other sign of toxicity was observed in all groups.
These results indicate that MF is active in vivo in murine experimental melanoma model without showing any direct antimelanoma activity in in vitro assays when used at doses mimicking the serum levels found in clinical practice in humans. We believe that the activation of the immune system following the administration of MF may be one of the mechanisms that explain the anti-tumoral effect of this drug.